Delhi Journal of Ophthalmology

Drug Delivery Innovation during Cataract Surgery: Are We Ready for Dropless Cataract Surgery?

Suresh K. Pandey, Vidushi Sharma
SuVi Eye Institute & Lasik Laser Center, Kota, Rajasthan, India

Editor-in-Chief, Delhi Journal of Ophthalmology, Dr R.P.Centre, AIIMS.

Corresponding Author:

Suresh K Pandey MBBS, MS
SuVi Eye Institute & Lasik Laser CenterC - 13
Talwandi, Kota,
Rajasthan 324 005India

Received: 02-JAN-2019 Accepted: 04-MAR-2019 Published Online: 05-MAY-2019

At present, drug administration options during cataract surgery include topical application. Subconjunctival application is not used now. Intracameral Injection is reserved for antibiotic supplement. Biodegradable implant had shown considerable utility in the management of retinal disorders (refractory macular edema). After the success of sustained-release drug delivery systems such as Retisert (fluocinolone acetonide intravitreal implant 0.59 mg, Bausch + Lomb, USA) and Ozurdex (dexamethasone intravitreal implant 0.7 mg, Allergan, USA), various drug delivery technologies are being developed to treat diseases of the eye. Encouraged by these, different ophthalmic tissue spaces to implant these reservoir-based drug delivery systems are also being explored. Clinical trials are under way to address the efficacy of transzonular drug delivery system (dropless cataract surgery). Indian pharmaceuticals are currently working to formulate a triamcinilone and moxifloxacin combination that can be used intra-operatively during cataract surgery.

Keywords :Dropless Cataract Surgery, Transzonular application of antibiotics and steroids, Intracameral injection of antibiotics